Arrowhead Pharmaceuticals: Strong Buy Rating Backed by Promising RNAi Pipeline and Strategic Partnerships

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on ARWR stock, giving a Buy rating on May 14.

Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Arrowhead Pharmaceuticals’ strong position in the RNA interference (RNAi) market. The company is on the cusp of launching its first commercial product, plozasiran, for familial chylomicronemia syndrome (FCS), with a significant FDA action date set for November 18, 2025. This potential launch is supported by impressive Phase 3 PALISADE trial results, which showed a substantial reduction in triglyceride levels and a decrease in the risk of acute pancreatitis, marking a significant milestone for RNAi therapies.
Additionally, Arrowhead’s robust pipeline, which includes late-stage and early-stage programs across various disease areas such as cardiometabolic, pulmonary, and CNS diseases, is progressing well. The company’s strategic partnerships, particularly with Sarepta for rare neuromuscular and CNS indications, further bolster its growth prospects. With a strong cash position and a validated TRiM platform, Arrowhead is well-positioned to transition into a multi-product company, delivering sustained value across high-impact disease areas. These factors collectively underpin Trucchio’s confidence in reiterating a Buy rating with a price target of $80.

In another report released on May 14, B.Riley Financial also initiated coverage with a Buy rating on the stock with a $38.00 price target.

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARWR in relation to earlier this year.